Healthcare [ 3/11 ] | Drug Manufacturers—Specialty & Generic [ 23/154 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 14, 22 | -0.00
Increased by
+94.50%
|
-0.01
Increased by
+66.67%
|
| Sep 27, 22 | -0.02
Increased by
+34.67%
|
-0.02
Decreased by
-32.43%
|
| May 16, 22 | -0.09
Decreased by
-26.95%
|
-0.02
Decreased by
-336.59%
|
| Feb 14, 22 | -0.02
Increased by
+37.14%
|
-0.03
Increased by
+24.14%
|
| Nov 15, 21 | -0.05
Decreased by
-2.63 K%
|
-0.02
Decreased by
-122.45%
|
| Sep 27, 21 | -0.04
Decreased by
-3.65 K%
|
-0.02
Decreased by
-53.06%
|
| May 17, 21 | -0.07
Decreased by
-840.00%
|
-0.02
Decreased by
-354.84%
|
| Feb 11, 21 | -0.03
Decreased by
-6.90 K%
|
-0.02
Decreased by
-59.09%
|
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 22 | 27.66 M
Increased by
+26.30%
|
-2.88 M
Increased by
+89.66%
|
Decreased by
-10.42%
Increased by
+91.81%
|
| Jun 30, 22 | 27.45 M
Increased by
+16.89%
|
-17.70 M
Increased by
+6.83%
|
Decreased by
-64.49%
Increased by
+20.29%
|
| Mar 31, 22 | 24.20 M
Increased by
+79.49%
|
-53.07 M
Decreased by
-108.46%
|
Decreased by
-219.32%
Decreased by
-16.14%
|
| Dec 31, 21 | 23.13 M
Increased by
+52.67%
|
-11.55 M
Decreased by
-21.24%
|
Decreased by
-49.94%
Increased by
+20.59%
|
| Sep 30, 21 | 21.90 M
Increased by
+61.96%
|
-27.85 M
Decreased by
-546.81%
|
Decreased by
-127.19%
Decreased by
-299.37%
|
| Jun 30, 21 | 23.48 M
Increased by
+58.02%
|
-19.00 M
Decreased by
-504.05%
|
Decreased by
-80.90%
Decreased by
-282.27%
|
| Mar 31, 21 | 13.48 M
Increased by
+65.30%
|
-25.46 M
Decreased by
-377.46%
|
Decreased by
-188.84%
Decreased by
-188.84%
|
| Dec 31, 20 | 15.15 M
Increased by
+377.04%
|
-9.53 M
Decreased by
-4.35 K%
|
Decreased by
-62.89%
Decreased by
-831.99%
|
| Rank | ETF | Shares | Market Value | Weight % in ETF |
|---|
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.